Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study

计划入组 25 人 · 首次发布于 2025 年 9 月 23 日

Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)

计划入组 72 人 · 首次发布于 2025 年 6 月 10 日

Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)

计划入组 70 人 · 首次发布于 2025 年 12 月 10 日

Metabolic dysfunction-associated steatohepatitis(Cellarity)

siRNA therapy (sc, metabolic dysfunction-associated steatohepatitis)

undisclosed program

METABOLIC THERAPY, INC.

United States

Metabolic Technologies, Inc.

United States

Associated Capital

United States

Madrigal's Resmetirom Nears Full Approval for NASH Cirrhosis Treatment Following Phase 3 Enrollment Completion

AI-Based Pathology Tool Validated for Scoring Metabolic Dysfunction-Associated Steatohepatitis

Multi-biotics Enhance Lenvatinib Sensitivity in MASH-Related HCC Organoids